Feb 27 |
Capricor Therapeutics Announces Upcoming Type-B Meeting with the FDA to Discuss Commercial Manufacturing Planning with an Aim to Expedite BLA Pathway for CAP-1002 in Duchenne Muscular Dystrophy
|
Feb 22 |
Capricor Therapeutics to Present Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Update on February 29
|
Feb 20 |
Capricor scales up manufacturing capacity for DMD therapy
|
Feb 20 |
Capricor Therapeutics Announces Manufacturing Scale-Up of CAP-1002 Production at New San Diego Facility as it Continues Plans Toward Commercialization
|
Feb 4 |
Market Sentiment Around Loss-Making Capricor Therapeutics, Inc. (NASDAQ:CAPR)
|
Jan 24 |
Capricor Therapeutics Announces Collaboration with the National Institutes of Health for Clinical Trial of Novel Exosome-Based Multivalent Vaccine for SARS-CoV-2
|
Dec 13 |
Capricor Therapeutics (NASDAQ:CAPR) shareholders are up 16% this past week, but still in the red over the last five years
|
Dec 11 |
Capricor Therapeutics Announces Continuation of Phase 3 HOPE-3 Trial of CAP-1002 in Duchenne Muscular Dystrophy Based on Completion of Interim Futility Analysis
|
Nov 16 |
Is Capricor Therapeutics (NASDAQ:CAPR) In A Good Position To Invest In Growth?
|
Nov 16 |
Capricor Therapeutics, Inc. (NASDAQ:CAPR) Q3 2023 Earnings Call Transcript
|